Cited by 1,058Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCancer Genomics and Diagnostics

The DOI matches its Crossref record; 103 of the 104 references it cites were found in a registry or an index.

Natural selection of tumor variants in the generation of “tumor escape” phenotypes

Open access

Khong, Hung T., Restifo, Nicholas P.·2002·Nature Immunology

Open this paper in CoChat — free account

Abstract

The idea that tumors must "escape" from immune recognition contains the implicit assumption that tumors can be destroyed by immune responses either spontaneously or as the result of immunotherapeutic intervention. Simply put, there is no need for tumor escape without immunological pressure. Here, we review evidence supporting the immune escape hypothesis and critically explore the mechanisms that may allow such escape to occur. We discuss the idea that the central engine for generating immunoresistant tumor cell variants is the genomic instability and dysregulation that is characteristic of the transformed genome. "Natural selection" of heterogeneous tumor cells results in the survival and proliferation of variants that happen to possess genetic and epigenetic traits that facilitate their growth and immune evasion. Tumor escape variants are likely to emerge after treatment with increasingly effective immunotherapies.

Integrity signals

Registry

Crossref · 10.1038/ni1102-999

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J., Lanier, L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 3,272
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Inhibition of death receptor signals by cellular FLIP
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,548
A cell culture model for T lymphocyte clonal anergy
Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance
Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., & Sakaguchi, S. (2002) · Nature Immunology · doi:10.1038/ni759 · Cited by 1,729
Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance
Sakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., Kuniyasu, Y., Nomura, T., Toda, M., & Takahashi, T. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820102.x · Cited by 1,505
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
CD4+CD25+ Immunoregulatory T Cells
McHugh, R. S., Whitters, M. J., Piccirillo, C. A., Young, D. A., Shevach, E. M., Collins, M., & Byrne, M. C. (2002) · Immunity · doi:10.1016/s1074-7613(02)00280-7 · Cited by 1,395
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
Hahne, M., Rimoldi, D., Schröter, M., Romero, P. J., Schreier, M. H., French, L. E., Schneider, P., Bornand, T., Fontana, A., Liénard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,236

Show all 104 references

Sorted by citations

Items 701–800 of 998

Vaccine Boosting CAR-T Cell Therapy: Current and Future Strategies
Ansah, E. O., Baah, A., & Agyenim, E. B. (2023) · Advances in Cell and Gene Therapy · doi:10.1155/2023/8030440 · Cited by 9
Stimulation through very late antigen‐4 and ‐5 improves the multifunctionality and memory formation of CD8+ T cells
Hosoi, H., Ikeda, H., Imai, N., Amaike, C., Wang, L., Orito, Y., Yamane, M., Ueno, H., Ideno, M., Nukaya, I., et al. (2014) · European Journal of Immunology · doi:10.1002/eji.201343969 · Cited by 9
Characterization of cytotoxicity-related gene expression in response to virulent Marek’s disease virus infection in the bursa of Fabricius
Chen, C., Xie, Q., Xue, Y., Ji, J., Chang, S., Ma, J., & Bi, Y. (2012) · Research in Veterinary Science · doi:10.1016/j.rvsc.2012.10.014 · Cited by 9
Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization
Corsini, E., Gelati, M., Calatozzolo, C., Alessandri, G., Frigerio, S., Francesco, M. A. D., Poiesi, C., Parati, E. A., Croci, D., Boiardi, A., et al. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0529-5 · Cited by 9
Complete Regression of Melanocytic Nevi: Correlation Between Clinical, Dermoscopic, and Histopathologic Findings in 13 Patients
Martín, J. M., Rubio, M., Bella, R., Jordá, E., & Monteagudo, C. C. (2012) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2012.06.017 · Cited by 9
Anti-tumor Immunity and Mechanism of Immunosuppression Mediated by Tumor Cells: Role of Tumor-Derived Soluble Factors and Cytokines
Deepak, P., & Acharya, A. (2010) · International Reviews of Immunology · doi:10.3109/08830185.2010.483027 · Cited by 9
The Requirements for CTL-Mediated Rejection of Cancer in Humans: NKG2D and Its Role in the Immune Responsiveness of Melanoma
Wang, E., Selleri, S., & Marincola, F. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2150 · Cited by 9
In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma
Donskov, F. N., Marcussen, N., Hokland, M., Fisker, R. V., Madsen, H. H. T., & von der Maase, H. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601587 · Cited by 9
Regulation of CTL responses to MHC‐restricted class I peptide of the gp70 tumour antigen by splenic parenchymal CD4+ T cells in mice failing immunotherapy with DISC–mGM‐CSF
Ahmad, M., Rees, R. C., McArdle, S., Li, G., Mian, S., Entwisle, C., Loudon, P. T., & Ali, S. (2005) · International Journal of Cancer · doi:10.1002/ijc.20976 · Cited by 9
Innate immunity in breast carcinoma.
Sfondrini, L., Balsari, A., & M�nard, S. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100301 · Cited by 9
Macrophage-mediated immunoediting drives ductal carcinoma evolution: Space is the game changerPreprint
Gatenbee, C., West, J., Baker, A. M., Guljar, N., Jones, J. L., Graham, T. A., Robertson‐Tessi, M., & Anderson, A. R. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/594598 · Cited by 9
Immune Escape
Whiteside, T. L., Campoli, M. R., & Ferrone, S. (2005) · Springer eBooks · doi:10.1007/1-4020-3623-x_3 · Cited by 9
Clinical implications and immune features of CENPN in breast cancer
Gui, Z., Tian, Y., Yu, T., Liu, S., Liu, C., & Zhang, L. (2023) · BMC Cancer · doi:10.1186/s12885-023-11376-2 · Cited by 8
Short‑chain fatty acids regulate hepatocellular carcinoma progression: A metabolic perspective on tumor immunity (Review)
Pan, D., Bao, Y., Lu, X., Gu, Q., Zhang, Y., & Zheng, Y. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5655 · Cited by 10
Pyroptosis: Turning Up the Heat on Cancer
Zhang, Z., & Lieberman, J. (2026) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082423-041848 · Cited by 9
The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens
Vredevoogd, D. W., Apriamashvili, G., & Peeper, D. S. (2021) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2021.100043 · Cited by 7
Chronic Stress Does Not Influence the Survival of Mouse Models of Glioblastoma
Lopes, M., de Castro, J. V., Pojo, M., Gonçalves, C. S., Martins, E. P., Coimbra, B., Sotiropoulos, I., Sousa, N., Rodrigues, A. J., & Costa, B. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.856210 · Cited by 8
Design of new drugs for medullary thyroid carcinoma
Li, Y., Luo, Z., Wang, X., Zhang, S., Hei, H., & Qin, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.993725 · Cited by 8
Mathematical Modeling of Tumor Immune Interactions: The Role of Anti-FGFR and Anti-PD-1 in the Combination Therapy
Li, C., Ren, Z., Yang, G., & Lei, J. (2024) · Bulletin of Mathematical Biology · doi:10.1007/s11538-024-01329-6 · Cited by 8
Total HLA Class I Antigen Loss with the Downregulation of Antigen-Processing Machinery Components in Two Newly Established Sarcomatoid Hepatocellular Carcinoma Cell Lines
Lei, W., Hsiung, S.-C., Wen, S.-H., Hsieh, C.-H., Chen, C., Wallace, C. G., Chang, C., & Liao, S. (2018) · Journal of Immunology Research · doi:10.1155/2018/8363265 · Cited by 8
Chimeric Antigen Receptors for the Tumour Microenvironment
Habib, R., Nagrial, A. M., Micklethwaite, K. P., & Gowrishankar, K. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-44518-8_8 · Cited by 8
Ecology of Fear: Spines, Armor and Noxious Chemicals Deter Predators in Cancer and in Nature
Peplinski, J., Malone, M. A., Fowler, K. J., Potratz, E. J., Pergams, A. G., Charmoy, K. L., Rasheed, K., Avdieiev, S. S., Whelan, C. J., & Brown, J. S. (2021) · Frontiers in Ecology and Evolution · doi:10.3389/fevo.2021.682504 · Cited by 8
Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer
Zhao, Y., Wang, Z., Shi, X., Liu, T., Yu, W., Ren, X., & Zhao, H. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231202307 · Cited by 8
Low-Dose Radiation Potentiates the Therapeutic Efficacy of Folate Receptor–Targeted Hapten Therapy
Sega, E. I., Lu, Y. J., Ringor, M., Leamon, C. P., & Low, P. S. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.02.010 · Cited by 8
Pathogenese und genetischer Hintergrund des Osteosarkoms
Baumhoer, D. (2017) · Der Pathologe · doi:10.1007/s00292-017-0365-y · Cited by 8
Development and Function of Natural Killer Cells and Its Importance in Cancer Immunotherapy
Paul, S., & Lal, G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809819-6.00009-5 · Cited by 8
Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists
Pourvaziri, A., Parakh, A., Biondetti, P., Sahani, D. V., & Kambadakone, A. R. (2020) · Abdominal Radiology · doi:10.1007/s00261-020-02531-5 · Cited by 8
The immunological and protective role of Baicalin in male rats treated with chemotherapy (Gemcitabine)
Qasim, M. T., & Al-Mayali, H. K. (2019) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1234/1/012065 · Cited by 8
Galectins
Sundblad, V., Mathieu, V., Robert Kiss, A., & Rabinovich, G. A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394296-8.00031-2 · Cited by 7
Development of autologous cytotoxic CD4+ T clones in a human model of B‐cell non‐Hodgkin follicular lymphoma
Mi, J., Manches, O., Wang, J., Perron, P., Weisbuch, S., Marche, P. N., Renversez, J., Bensa, J., Sotto, J., Cahn, J.-Y. Y., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06294.x · Cited by 8
Tumor-Localized Ligation of CD3 and CD28 with Systemic Regulatory T-Cell Depletion Induces Potent Innate and Adaptive Antitumor Responses
Lee, C.-H., Chiang, Y., Chang, S., Chong, C.-L., Cheng, B.-M., & Roffler, S. R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2311 · Cited by 8
Specific loading of oncolytic VSV on CAR enhances CAR-T cell signaling and antitumor activity
Xing, F., Wang, X., Li, Z., Zheng, L., Huang, Z., Guo, J., Xi, Z., Feng, H., Xia, B., Lin, Y., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241851 · Cited by 7
Immunological surveillance against cancer across mammals
Vincze, O., Minias, P., Corthay, A., Colchero, F., Lemaître, J., Maille, L., Malkócs, T., Hagemann, J., Conde, D. A., Pavard, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65286-x · Cited by 10
Current status of vaccine immunotherapy for gastrointestinal cancers
Suzuki, N., Shindo, Y., Nakajima, M., Tsunedomi, R., & Nagano, H. (2023) · Surgery Today · doi:10.1007/s00595-023-02773-y · Cited by 7
Identification of immunogenic cell death-related damage-related molecular patterns (DAMPs) to predict outcomes in patients with head and neck squamous cell carcinoma
Zhang, J., Shi, X., Wang, M., Zhai, R., Wang, M., Gong, Z., Ni, Z., Xu, T., Zhu, W., & Liu, L. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05779-2 · Cited by 7
Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors
Wilczyński, J. R., & Nowak, M. (2013) · Springer eBooks · doi:10.1007/978-3-7091-1300-4_8 · Cited by 7
Immunotherapies in CLL
Park, J. H., & Brentjens, R. J. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-8051-8_11 · Cited by 7
Investigation of possible associations between tryptophan/kynurenine status and FOXP3 expression in colorectal cancer
Ay, E. N., Demirkol, Ş., Hakan, M. T., Horozoğlu, C., Arıkan, S., Doğan, M. B., Akyüz, F., Hepokur, C., & Yaylım, İ. (2022) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2022.2040050 · Cited by 7
Biostimulatory Manganese-Doped Nanoneedle for MRI-Visual Bispecific Antibody Gene Delivery and Immunosuppression Reversal as a Cancer Immunotherapy Strategy
Cai, J., Jiang, S., Liao, J., Huiping, F., Chen, P., Shi, S., Huang, S., Chen, G., Xu, J., & Wang, Z. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.142242 · Cited by 7
Antigen-Receptor Gene-Modified T Cells For Treatment Of Glioma
Ikeda, H., & Shiku, H. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3146-6_16 · Cited by 7
Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma
Mazzocco, M., Martini, M., Rosato, A., Stefani, E., Matucci, A., Santa, S. D., Sanctis, F. D., Ugel, S., Sandri, S., Ferrarini, G., et al. (2015) · Immunology · doi:10.1111/imm.12477 · Cited by 7
SANTAVACTM: Summary of Research and Development
Lokhov, P. G., Mkrtichyan, M., Mamikonyan, G., & Balashova, E. E. (2019) · Vaccines · doi:10.3390/vaccines7040186 · Cited by 7
Evolutionary Design in Biological Physics and Materials Science
Yang, M., Park, J.-M., & Deem, M. W. (2007) · Springer eBooks · doi:10.1007/3-540-35284-8_20 · Cited by 7
Cancer Immunosurveillance: Immunoediting
Lussier, D. M., & Schreiber, R. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.17001-8 · Cited by 7
Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy
Beelen, N. A., Valckx, V. T. C., Bos, G. M. J., & Wieten, L. (2024) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2024.101568 · Cited by 6
Immunohistochemical Expression of Sperm-Associated Antigen 9 in Nonmelanoma Skin Cancer
Seleit, I., Bakry, O. A., Samaka, R. M., & Malak, M. A. (2014) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000126 · Cited by 6
Healthy Cells Functionally Present Tap-Independent Ssr1 Peptides: Implications for Selection of Clinically Relevant Antigens
de Waard, A. A., Verkerk, T., Hoefakker, K., van der Steen, D. M., Jongsma, M. L. M., Kadosh, D. M., Bliss, S., de Ru, A. H., Admon, A., van Veelen, P. A., et al. (2020) · iScience · doi:10.1016/j.isci.2021.102051 · Cited by 6
La inhibición de los puntos de control inmunológico, una terapia en evolución: remembranza del Premio Nobel de Medicina 2018
Cárdenas, A., Bocchieri-Oyarce, P. A., Méndez-Laport, C. R., Zolezzi, J. M., & Ríos, J. A. (2022) · Revista médica de Chile · doi:10.4067/s0034-98872022000100093 · Cited by 6
An Overview of Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Canine Tumors: How Far Have We Come?
Armando, F., Mazzola, F., Ferrari, L., & Corradi, A. (2022) · Veterinary Sciences · doi:10.3390/vetsci10010019 · Cited by 7
Immuno-oncologic signature of malignant transformation in oral squamous cell carcinoma
Elnaggar, M., Chaisuparat, R., Ghita, I., Bentzen, S. M., Dyalram, D., Ord, R. A., Lubek, J. E., & Younis, R. H. (2023) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2023.07.009 · Cited by 6
Peto’s “Paradox” and Six Degrees of Cancer Prevalence
Szász, A. (2024) · Cells · doi:10.3390/cells13020197 · Cited by 7
Xenovaccinotherapy for Cancer
Seledtsov, V. I., Shishkov, A. A., & Seledtsov, G. V. (2011) · InTech eBooks · doi:10.5772/23671 · Cited by 6
Inhibitory B7 Family Members in Human Ovarian Carcinoma
Wei, S., Curiel, T. J., Coukos, G., Liu, R., & Zou, W. (2008) · Springer eBooks · doi:10.1007/978-0-387-68969-2_21 · Cited by 6
Cancer vaccine therapy based on peptides
Katsuda, M., & Yamaue, H. (2017) · Trends in Immunotherapy · doi:10.24294/ti.v1.i1.41 · Cited by 6
Breakthroughs in cancer gene therapy
Liu, K. (2003) · Seminars in Oncology Nursing · doi:10.1016/s0749-2081(03)00049-4 · Cited by 6
Experimental therapeutic approaches to adenocarcinoma: The potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer
Mortara, L., Giuliani, L., Barbaro, A. D. L., Accolla, R. S., & Noonan, D. M. (2007) · Surgical Oncology · doi:10.1016/j.suronc.2007.10.045 · Cited by 6
Cancer Immunotherapy: Will Expanding Knowledge Lead to Success in Pediatric Oncology?
Fry, T. J., & Lankester, A. C. (2008) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2007.10.015 · Cited by 6
Immunology and Immunotherapy of Ovarian Cancer
Wilczyński, J. R., & Nowak, M. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_22 · Cited by 6
Editorial
Emens, L. A. (2006) · International Reviews of Immunology · doi:10.1080/08830180600992373 · Cited by 6
Generation of αCD11b-CpG antibody conjugates for the targeted stimulation of myeloid cells
Balneger, N., Kroesen, M., Lindau, D., Wassink, M., Boon, L., den Brok, M. H., Büll, C., & Adema, G. J. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.017 · Cited by 5
IEDB and CEDAR: Two Sibling Databases to Serve the Global Scientific Community
Blazeska, N., Koşaloğlu‐Yalçın, Z., Vita, R., Peters, B., & Sette, A. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3239-0_9 · Cited by 5
Chemotherapy-induced PTEN-L secretion promotes the selection of PTEN-deficient tumor cells
Wang, M., Pan, Z., Chu, X., Yao, X., Duan, X., Wan, J., Lou, X., Li, W., Yan, Y., Chen, L., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03059-y · Cited by 5
Theranostic Rhenium(I)-Based ER-Phagy Retardant Promotes Immunogenic Cell Death
Liang, H., Ling, Y., Wang, J., Shen, Q., Li, Z., & Tan, C. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01948 · Cited by 5
Influence of Immune Surveillance and Immune Privilege on Formation of Intraocular Tumors
Chen, P. W., & Ksander, B. R. (2007) · KARGER eBooks · doi:10.1159/000099278 · Cited by 5
Screening for Distress in the Radiation Therapy Department: Distress Incidence by Sex, Treatment Intent, and Ethnicity
Bodnarchuk, T. W., Stavrou, S., & Gantefoer, A. (2014) · Journal of medical imaging and radiation sciences · doi:10.1016/j.jmir.2014.02.001 · Cited by 5
Cancer Immunotherapy: Will Expanding Knowledge Lead to Success in Pediatric Oncology?
Fry, T. J., & Lankester, A. C. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.11.010 · Cited by 5
Immune oppression array elucidating immune escape and survival mechanisms in uveal melanoma
Hou, F., Huang, Q., Hu, D., Jonas, J. B., & Wei, W. (2016) · International Journal of Ophthalmology · doi:10.18240/ijo.2016.12.01 · Cited by 5
Yin-Yang-1 decreases Fas-induced apoptosis in acute lymphoblastic leukemia under hypoxic conditions: its implications in immune evasion
Martínez-Torres, E., López-Pérez, T. V., Morales-Martínez, M., & Huerta‐Yépez, S. (2020) · Boletín Médico del Hospital Infantil de México · doi:10.24875/bmhim.20000187 · Cited by 5
SPARTIN: a Bayesian method for the quantification and characterization of cell type interactions in spatial pathology data
Osher, N., Kang, J., Krishnan, S., Rao, A., & Baladandayuthapani, V. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1175603 · Cited by 5
p53-Based Immunotherapy of Cancer
Leo, A. B. D. (2004) · KARGER eBooks · doi:10.1159/000082504 · Cited by 5
Increased Susceptibility to Immune Destruction of B16BL6 Tumor Cells Engineered to Express a Novel Pro-Smac Fusion Protein
Rüttinger, D., Li, R., Poehlein, C. H., Haley, D., Walker, E., Hu, H., & Fox, B. A. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318158fd16 · Cited by 5
Gene transfer preferentially selects MHC class I positive tumour cells and enhances tumour immunogenicity
Hacker, U. T., Schildhauer, I., Barroso, M. C., Kofler, D. M., Gerner, F. M., Mysliwietz, J., Buening, H., Hallek, M. J., & King, S. B. S. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0035-4 · Cited by 5
Effect of B7.1 Costimulation on T-Cell Based Immunity against TAP-Negative Cancer Can Be Facilitated by TAP1 Expression
Li, X., Liu, Y., Knight, D., Odaka, Y., Mathis, J. M., Shi, R., Glass, J., & Zhang, Q.-J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006385 · Cited by 5
Immunization with a HSP65–HER2 fusion peptide selectively eliminates HER2+ B16 melanoma cells in a xenograft tumor mouse model
Wang, J., Wang, X., Chen, Y., Wan, M., Xiang, Z., Wu, X., Wei, H., Wang, L., Zhang, P., Wang, L., et al. (2012) · Tumor Biology · doi:10.1007/s13277-012-0529-6 · Cited by 5
Accurate apoptosis measurement requires quantification of loss of expression of surface antigens and cell fragmentation
Díaz, D., I, A. P., Barcenilla, H., Monserrat, J., Sánchez, M. A., Reyes, E., Hernández-Fuentes, M. P., de la Hera, A., Órfão, A., & Álvarez‐Mon, M. (2006) · Cytometry Part A · doi:10.1002/cyto.a.20251 · Cited by 5
Tumor growth characteristics of the Walker 256 AR tumor, a regressive variant of the rat Walker 256 A tumor
Guimarães, F., Schanoski, A. S., Cavalcanti, T. C. S., Juliano, P. B., Vieira-Matos, A. N., & Rettori, O. (2010) · Brazilian Archives of Biology and Technology · doi:10.1590/s1516-89132010000500014 · Cited by 5
A theory of multi-site vaccination for cancer
Yang, M., Park, J.-M., & Deem, M. W. (2006) · Physica A Statistical Mechanics and its Applications · doi:10.1016/j.physa.2006.01.072 · Cited by 5
Overview of melanoma vaccines and promising approaches
Panelli, M. C., Wang, E., Monsurrò, V., Jin, P., Zavaglia, K. M., Smith, K., Ngalame, Y., & Marincola, F. M. (2004) · Current Oncology Reports · doi:10.1007/s11912-004-0069-3 · Cited by 5
Prospects for Immunotherapy of MHC Class I-Deficient Tumours
Bubenik, J. (2003) · Folia Biologica · doi:10.14712/fb2003049030095 · Cited by 5
Targeting cytokine/chemokine signaling to convert immunologically cold tumors into hot: Emerging strategies in cancer immunotherapy
Park, J. H., Lee, D. U., Jeong, J., Jung, K. H., & Hong, S. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.03.017 · Cited by 4
Implication of Amyloid Precursor-like Protein 2 Expression in Cutaneous Squamous Cell Carcinoma Pathogenesis
HUANG, X., YANG, J., XI, H., ZHANG, M., Oh, Y., Jin, Z., & ZHENG, Z. (2023) · In Vivo · doi:10.21873/invivo.13452 · Cited by 4
Tumor-associated antigen targets for novel immune-based strategies in prostate cancer
Bhasin, A., Mille, P. J., Eturi, A., Iskander, A. J., Tester, W. J., & Zarrabi, K. K. (2024) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2023.46 · Cited by 4
Emerging Cancer Immunotherapies: Cutting-Edge Advances and Innovations in Development
Maccagno, M., Tapparo, M., Saccu, G., Rumiano, L., Kholia, S., Silengo, L., & Sanchez, M. B. H. (2024) · Medical Sciences · doi:10.3390/medsci12030043 · Cited by 5
Why Do CD8+ T Cells become Indifferent to Tumors: A Dynamic Modeling Approach
Campbell, C., Zhang, R., Haley, J. S., Liu, X., Loughran, T. P., Schell, T. D., Albert, R., & Thakar, J. (2011) · Frontiers in Physiology · doi:10.3389/fphys.2011.00032 · Cited by 4
Antigenic stimulation with cytochrome P450 2J expressed in mouse hepatocellular carcinoma cells regulates host anti-tumour immunity
Homma, S., Koido, S., Sagawa, Y., Suzuki, H., Komita, H., Nagasaki, E., Takahara, A., Horiguchi‐Yamada, J., Tajiri, H., Zeldin, D. C., et al. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03900.x · Cited by 4
Estudio descriptivo dermatoscópico de los nevos melanocíticos con despigmentación sin halo clínico
Martín, J. M., Núñez, J. E., López, V., Rubio, M., Monteagudo, C. C., & Jordá, E. (2011) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2010.10.013 · Cited by 4
Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones
Mylin, L. M., Schell, T. D., Epler, M., Kusuma, C. M., Assis, D., Matsko, C., Smith, A. C. G., Allebach, A., & Tevethia, S. S. (2007) · Virology · doi:10.1016/j.virol.2007.02.007 · Cited by 4
γδ T Cells Number, CD200, and Flt3 Expression Is Associated with Higher Progression Free Survival in Patients with Chronic Myeloid Leukemia
Molina-Aguilar, R., Montiel‐Cervantes, L. A., Anguiano-Peñaloza, S. V., Lezama, R. A., Vela‐Ojeda, J., & Reyes‐Maldonado, E. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.01.013 · Cited by 4
A mechanistic systems pharmacology modeling platform to investigate the effect of PD-L1 expression heterogeneity and dynamics on the efficacy of PD-1 and PD-L1 blocking antibodies in cancer
Bazzazi, H., & Shahraz, A. (2021) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2021.110697 · Cited by 4
Recent Reviews on Dendrimers as an Immunotherapy-based Nanosystem for the Effective Treatment of Cancer
Mandal, U. K., & Kumar, M. (2022) · Drug Delivery Letters · doi:10.2174/2210303112666220422102459 · Cited by 4
NGAL Mediates Anaplastic Thyroid Carcinoma Cells Survival Through FAS/CD95 Inhibition
Crescenzi, E., Mellone, S., Gragnano, G., Iaccarino, A., Leonardi, A., & Pacifico, F. (2023) · Endocrinology · doi:10.1210/endocr/bqad190 · Cited by 4
A probable etiological role for Merkel cell polyomavirus in the development of Merkel cell carcinoma
Horváth, K. B., Pankovics, P., Battyáni, Z., Kálmán, E., & Reuter, G. (2013) · Orvosi Hetilap · doi:10.1556/oh.2013.29525 · Cited by 4
Breaking tolerance with engineered class I antigen-presenting molecules
Parks, C. A., Henning, K. R., Pavelko, K. D., Hansen, M. J., Keulen, V. P. V., Reed, B. K., Stone, J. D., Schrum, A. G., Gil, D., Kranz, D. M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807465116 · Cited by 4
HLA class I-restricted T cell epitopes isolated and identified from myeloid leukemia cells
Nyambura, L. W., Muñoz, A. A., le Coutre, P., & Walden, P. (2019) · Scientific Reports · doi:10.1038/s41598-019-50341-7 · Cited by 4
Genetic Immunotherapy Approaches
Shaw, D. R., & LoBuglio, A. F. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-785-7_9 · Cited by 4
Oncoimmunology: Some fundamental problems of cancer immunotherapy
Nedospasov, S. A., & Kuprash, D. V. (2007) · Molecular Biology · doi:10.1134/s0026893307020124 · Cited by 4
Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats
Vallebona, P. S., Rasi, G., Pierimarchi, P., Bernard, P., Guarino, E., Guadagni, F., & Garaci, E. (2004) · International Journal of Cancer · doi:10.1002/ijc.20063 · Cited by 4
Targeting HMGB1 in the Treatment of Non-Small Cell Lung Adenocarcinoma
Anderson, B. J., Vue, M., Gayluak, N., Brown, S. J., Bemis, L., & Simmons, G. E., Jr. (2021) · Onco · doi:10.3390/onco1010004 · Cited by 4
Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer
Porta, C. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.1.141 · Cited by 4
Vaccination with T cell-defined antigens
Panelli, M. C., Wang, E., Monsurrò, V., Jin, P., Zavaglia, K. M., Smith, K., Ngalame, Y., & Marincola, F. M. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.5.697 · Cited by 4

Authors: Khong, H. T., & Restifo, N. P.
Affiliations: National Institutes of Health (US)
Corresponding author: Khong, Hung T.
Restifo, Nicholas P.
ORCID: Khong, Hung T.
Restifo, Nicholas P.
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2002-11
Volume: 3
Issue: 11
Pages: 999-1005
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni1102-999
PMC: PMC1508168
OpenAlex: W2051940153
Cited by: 1,058
References: 104
Citations by year: 2026: 17 · 2025: 18 · 2024: 33 · 2023: 45 · 2022: 35 · 2021: 28 · 2020: 40 · 2019: 39 · 2018: 38 · 2017: 51 · 2016: 32 · 2015: 43 · 2014: 41 · 2013: 63 · 2012: 44
FWCI: 5.47
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
University of Regensburg Publication Server (University of Regensburg)
Funders: National Institutes of Health (Z99 CA999999)
National Cancer Institute (Z01BC010763)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: tumor immune evasion, natural selection, tumor heterogeneity, tumor variants, genomic instability, immunoresistance, epigenetic regulation, cancer immunotherapy resistance, immune evasion
MeSH terms: Animals, Antigens, Neoplasm, HLA Antigens, Humans, Immunologic Surveillance, Immunotherapy, Killer Cells, Natural, Neoplasms, Selection, Genetic, T-Lymphocytes, Cytotoxic, Immunodominant Epitopes, Cytokines, Apoptosis, Models, Immunological, Disease Progression, Tumor Escape, T-Lymphocytes, Regulatory, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Natural selection of tumor variants in the generation of “tumor escape” phenotypes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks